Drug Database
Back to search

Poland· PL-100499913

Tocilizumab STADA

A tocilizumab product containing tocilizumabum, registered in Poland by STADA Arzneimittel AG. The same ATC class is registered in 15 of our 19 countries.

ATC L04AC07

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTocilizumab STADAATCL04AC07REGISTER NO.PL-100499913PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tocilizumabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tocilizumab is registered in 15 of 19 countries.

Countries holding a registration under ATC L04AC07 (tocilizumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search tocilizumab products by name

Tocilizumab · ATC L04AC07

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tocilizumab costs, country by country.

Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tocilizumab · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$29.63
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Tocilizumabum
Manufacturer
STADA Arzneimittel AG
Country
Poland (PL)
ATC code
L04AC07
ATC class
Tocilizumab
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    04011548053713
  • gtin
    04011548053690
  • gtin
    04011548053706

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

263 interactions on record for tocilizumab.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tocilizumab against other medicinesHow interaction checks work

Tocilizumab · interactions on record

263 records

  • 38 severe
  • 218 moderate
  • 7 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tocilizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tocilizumab products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Tofidence
  • Iceland · Avtozma, Roactemra
  • Liechtenstein · Avtozma, Roactemra
  • Norway · Avtozma, Roactemra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6e69af84-dd88-44c3-8ff8-9a44f47aff67
GET /v1/drugs/6e69af84-dd88-44c3-8ff8-9a44f47aff67?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "20 mg/ml",
  "packaging": "04011548053713 ¦ Rpz ¦ EU/1/24/1825/005 ¦ 157067\n1 fiol. 20 ml\n04011548053690 ¦ Rpz ¦ EU/1/24/1825/001 ¦ 157068\n1 fiol. 4 ml\nRpz ¦ EU/1/24/1825/004 ¦ 157069\n4 fiol. 10 ml\nRpz ¦ EU/1/24/1825/006 ¦ 157070\n4 fiol. 20 ml\n04011548053706 ¦ Rpz ¦ EU/1/24/1825/003 ¦ 157071\n1 fiol. 10 ml\nRpz ¦ EU/1/24/1825/002 ¦ 157072\n4 fiol. 4 ml",
  "substance": "Tocilizumabum 20 mg/ml",
  "common_name": "Tocilizumabum",
  "pl_product_id": "100499913",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about tocilizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console